Cargando…
Use of Drotrecogin Alfa (Activated) in Bariatric Surgery Patients with Severe Sepsis Syndrome: Experience in an Urban Community Teaching Hospital
Background: Severe sepsis syndrome (SSS) and septic shock have an associated mortality ranging from 31 to 60%. Drotrecogin alfa (activated), activated protein C (APC), has been shown in a recent trial to decrease mortality from 44 to 31% in patients with SSS and a high risk of death. We present 3 pa...
Autores principales: | Savel, Richard H, Pulipati, Ravi C, Mangone-Cholewczynski, Connie, Lazzaro, Richard S, Macura, Jerzy M, Lehman, Herbert E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7102287/ https://www.ncbi.nlm.nih.gov/pubmed/14980044 http://dx.doi.org/10.1381/096089204772787392 |
Ejemplares similares
-
Introduction: severe sepsis and drotrecogin alfa (activated)
por: Artigas, Antonio, et al.
Publicado: (2007) -
Clinical trials in severe sepsis with drotrecogin alfa (activated)
por: Laterre, Pierre-François
Publicado: (2007) -
Timing of drotrecogin alfa (activated) treatment in severe sepsis
por: Choi, Goda, et al.
Publicado: (2006) -
Is Drotrecogin alfa (activated) for adults with severe sepsis, cost-effective in routine clinical practice?
por: Sadique, M Zia, et al.
Publicado: (2011) -
The safety profile of drotrecogin alfa (activated)
por: Fumagalli, Roberto, et al.
Publicado: (2007)